EP0000951B1 - Pharmaceutical formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders - Google Patents

Pharmaceutical formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders Download PDF

Info

Publication number
EP0000951B1
EP0000951B1 EP78100754A EP78100754A EP0000951B1 EP 0000951 B1 EP0000951 B1 EP 0000951B1 EP 78100754 A EP78100754 A EP 78100754A EP 78100754 A EP78100754 A EP 78100754A EP 0000951 B1 EP0000951 B1 EP 0000951B1
Authority
EP
European Patent Office
Prior art keywords
imidazole
pharmaceutically acceptable
carbon atoms
acid addition
addition salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP78100754A
Other languages
German (de)
French (fr)
Other versions
EP0000951A1 (en
Inventor
Peter Brian Thorogood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB7834106A external-priority patent/GB2006752B/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of EP0000951A1 publication Critical patent/EP0000951A1/en
Application granted granted Critical
Publication of EP0000951B1 publication Critical patent/EP0000951B1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
    • C07C17/16—Preparation of halogenated hydrocarbons by replacement by halogens of hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring

Definitions

  • the present invention relates to imidazole derivatives and salts thereof, to their synthesis and intermediates therefor, to pharmaceutical formulations containing such compounds and to the use of these componds in medicine.
  • Thromboxane A 2 (TXA,), a potent stimulator of blood platelet aggregation, is produced, in platelets, from the prostaglandin endoperoxides PGG 2 and PGH 2 .
  • Prostacyclin (PGI 2 ) which has potent anti-aggregatory activity, is also produced (in blood vessel walls) from PGG 2 and PGH 2 and it has been suggested that a balance between the production of TXA 2 and PGI 2 is the controlling factor in thrombus formation. It would, in consequence, be desirable in the treatment and prophylaxis of thrombo-embolic disorders to be able to selectively inhibit TXA 2 synthetase, thereby favouring the production of the anti-aggregatory agent PGI 2 .
  • Imidazole and 1-methylimidazole are known to provide some degree of inhibition of the enzymic conversion of the endoperoxides (PGG 2 and PGH 2 ) to thromboxane A 2 by platelet microsomes (Moncada et al., Prostaglandins, 13/4, 611-618, 1977).
  • Certain 1-(C 10-19 )hydrocarbyl-imidazoles have been described as being capable of lowering serum cholesterol levels (U.K. Patent No. 1 364 312; Biochem. Pharmacol. 24, 1902-1903, 1975).
  • German Auslegeschrift 1213413 describes a process for the preparation of a broad class of 1- alkenyl and 1-alkylimidazoles optionally substituted by alkyl groups in the 2,3- and/or 5-positions.
  • the resulting imidazoles are described in the specification as being useful as intermediates for the preparation of pest control and textile treatment agents.
  • the inhibitory potency of several derivatives of imidazole and 1-substituted imidazoles, such as 1-methylimidazole on thromboxane synthetase is known from Biochemical and Biophysical Research Communications, Vol. 80, No. 1 (1978), 236-242.
  • the authors of this article report that the inhibitory potency of 1-substituted imidazoles is increased with increasing chain length, and state that 1-nonyl- imidazole and 1-(2-isopropylphenyl)imidazole were found to possess the highest potency.
  • the best activities are obtained with compounds wherein the 1-substituent on the imidazole ring is a straight chain alkyl group.
  • the reference gives no information as to the 1-substituted imidazoles carrying cycloalkyl or cycloalkenyl groups of 4 to 9 carbon atoms or alkyl radicals of from 4 to 7 carbon atoms or alkenyl or alkynyl radicals of from 4 to 9 carbon atoms.
  • TXA 2 synthetase may be inhibited by 1-substituted imidazoles of formula (I) and pharmaceutically acceptable acid addition salts thereof.
  • the compounds of formula (I) and their salts are hereinafter referred to as the "active compounds”.
  • the compounds of formula (1) are:- in which A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of from 1 to 3 carbon atoms, n is 0 or 1, and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9, preferably from 5 to 8, carbon atoms and optionally substituted by one, two, three or more alkyl radicals each containing from 1 to 4 carbon atoms, or, when n is 1, A and R together form a straight-chain alkyl radical of from 4 to 7 carbon atoms or an alkenyl or alkynyl group of from 4 to 9 carbon atoms.
  • a novel class of compounds within the scope of formula (I) are those of formula (la): in which A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of from 1 to 3 carbon atoms and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9, preferably from 5 to 8, carbon atoms and optionally substituted by one or more alkyl radical each containing from 1 to 4 carbon atoms, with the proviso that when A is a methylene radical, R is not unsubstituted cyclohexyl.
  • cycloalkyl radicals are cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl; cycloalkenyl radicals include cyclohex-3-enyl, cyclopentyl, and 1,4-cyclohexadienyl; alkenyl radicals include pent-2-enyl and pent-4-enyl.
  • a valuable class of compounds of formula (I) are those in which n is 1, R is cyclohexyl, cyclohexyl, cycloheptyl, cyclooctyl, or cycloalkenyl of 6 to 8 carbon atoms, and A is -cH 2 or ⁇ (CW 2 ) 2 ⁇ .
  • Compounds of formula (I) or (la) may also be used pharmaceutically acceptable acid addition salts.
  • Especially preferred compounds include:
  • the compounds of formula (I) are more potent inhibitors of TXA 2 synthetase.
  • the compounds of formula (I) also do not produce the side-effects found with imidazole upon in vivo administration.
  • the compounds of formula (I) are further capable of inhibiting platelet aggregation in vivo and also are capable of disaggregating platelet clumps.
  • Imidazoles of formula (I) and acid addition salts thereof may be made by any method known in the art for the synthesis of compounds of analogous structure. In general these methods comprise linking the imidazole ring to the remainder of the molecule; converting a precursor molecule by elimination of a functional group from the imidazole ring; and formation of the desired compound from a corresponding imidazoline, pyrazole or unsaturated analogue.
  • a most convenient method of synthesis involves the reaction of imidazole (formula II) or a salt thereof with an alkylating agent of formula (III): wherein R and A are as defined in formula (I) and Z is a leaving group.
  • This reacion is well established in the literature, and the leaving group may be chosen from a variety of substituents but especially halo, preferably chloro or bromo, or from p-toluenesulphonyloxy but other arylsulphonyloxy, alkane- sulphonyloxy or aralkylsulphonyloxy radicals may be used.
  • the reaction is preferably performed in the presence of an acid acceptor, for example an alkali metal alkoxide such as sodium methoxide or potassium tertiary butoxide in the presence of a corresponding alkanol.
  • an acid acceptor for example an alkali metal alkoxide such as sodium methoxide or potassium tertiary butoxide in the presence of a corresponding alkanol.
  • a hydrohalogenic acid e.g. hydrochloric acid or a Lewis acid such as aluminium chloride: see Japanese Patent Kokai No. 131577/77
  • an alkanol (Z OH) or
  • a dehydrating agent such as phosphate acid, or a phosphate (see Japanese Patent Publication No. 5 1 105 060), sulphuric acid or sulphates (see Japanese Patent Publication No. 5 1 105 061 ).
  • precursor molecules which may be converted to a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof are substituted imidazole derivatives of formula (IV) or addition salts thereof wherein A and R are as defined in formula (I), and Q 1 , Q 2 and Q 3 are the same or different, at least one being selected from thio (-SH), alkylthio (-Salkyl wherein alkyl has 1 to 4 carbon atoms) and halo preferably chloro or bromo, the remaining radical or radicals being selected from a radical having the same function or from hydrogen.
  • the reaction conditions are chosen according to the nature of the radicals Q 1 , Q 2 and Q 3.
  • Desulphurisation may be performed by oxidative or reductive procedures using for example nitric acid or Raney nickel; and reductive dehalogenation by the use of zinc and acetic acid or Raney nickel or other reagents known in the literature.
  • Another class of examples include carboxyimidazoles or derivatives thereof of formula (VI): wherein A and R are as defined in formula (I), at least one of R 1 , R 2 and R 4 is carboxyl or a derivative thereof (for example an ester such as an alkyl ester, an acid halide such as the chloride, or the nitrile) and the other(s) is hydrogen or carboxyl or a derivative as described.
  • the compounds of formula (VI) may be converted into the imidazoles of formula (I) by any suitable decarboxylation conditions which may simply comprise heating the compounds with or without a catalyst such as copper.
  • the imidazoles of formula (I) may also be made a compound of formula (VII): is 1-imidazolidine, 1-imidazole or 1-pyrazole, A is a straight or branched saturated or unsaturated acyclic hydrocarbon radical, and R 3 is a cycloalkyl or cycloalkenyl radical of from 4 to 9 carbon atoms optionally substituted by alkyl as defined in formula (I), provided that at least one of A 1 and R 3 is other than 1-imidazole, a saturated acyclic hydrocarbon and an optionally substituted cycloalkyl group respectively as defined in formula (I).
  • an imidazoline (VIII): wherein one of--- - represents an extra bond and A and R are defined in formula (I) may be dehydrogenated to the corresponding imidazole in the presence of a catalyst for example by heating to 250°C in the presence of palladium, nickel or platinum under pressure, or by heating with a dehydrogenating agent such as selenium or copper oxide.
  • the 1-pyrazole compounds (VII) may be treated with ultra-violet irradiation, optionally under an inert atmosphere (e.g. argon) in for example 1,2-dimethoxyethane at room or elevated temperatures (see for example "Ring Transformations of Heterocycles" edited van der Plas, Academic Press, 1973 at page 261).
  • the unsaturated imidazoles of formula (I) (in formula (VII), A and/or R 3 are unsaturated) may be reduced to the corresponding saturated compounds with a noble metal catalyst, for example platinum or palladium in alkanol.
  • the intermediates for use in the above described reactions may also be made by conventional methods known in the art.
  • the 1-pyrazole and 1-imidazoline intermediates (formula (VII) may be prepared by alkylation of pyrazole and imidazoline in an analogous manner to that described above for preparation of the corresponding imidazoles.
  • the intermediates of formula (III) may be made in known manner preferably by halogenation of the corresponding alcohols (formula (III).
  • Z -OH) where in such compounds R is cycloalkenyl; the alcohol is conveniently prepared by the Prins reaction from the cycloalkene and paraformaldehyde (Bull. Chem. Soc. Japan 46/8, 2512-5, 1973).
  • substituted imidazole intermediates of formula (IV) may be made in known manner, for example see “Imidazole and its derivatives” Part I. Ed. K. Hofmann, Interscience Publishers In. New York, 1973.
  • 2-thioimidazoles of formula (IV) may be made by cyciisation of an acetal of formula (IX): with thiocyanate, wherein R 5 is alkyl.
  • the pharmaceutically acceptable addition salts of the compounds of formula (I) may be prepared by any method known in the art. In particular they may be prepared by treating the parent imidazole with the appropriate acid.
  • Examples of the addition salts of the compounds of formula (I) include those salts derived from the following acids: oxalic, hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salycyclic, succinic, toluene-p-sulphonic, tartaric, acetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic and benzene-sulphonic.
  • the imidazoles of formula (I) may be used in conjunction with a phosphodiesterase inhibitor, which provides a further, synergistic increase in effect, as it acts against platelet aggregation by a different pathway.
  • Suitable phosphodiesterase inhibitors for use in potentiating the anti-aggregatory effects of the active compounds include as such or as pharmaceutically acceptable salts:-
  • the active compounds are particularly useful in the treatment and/or prophylaxis of thrombo-embolic disorders in mammals, including man. It is to be understood that the term "thrombo-embolic disorders" includes those disorders whose etiology is associated with platelet aggregation.
  • the active compounds are useful wherever it is desired to inhibit platelet aggregation and/or to reduce the adhesive character of platelets, and consequently to treat or prevent the formation of thrombi in mammals, including man.
  • the compounds are useful in the treatment and prevention of myocardial infarcts cerebro-vascular thrombosis and ischaemic peripheral vascular disease; to treat and prevent post-operative thrombosis; and to promote patency of vascular grafts following surgery.
  • the active compounds are also useful as an addition to blood, blood products, blood substitutes, and other fluids which are used in artificial extra-corporeal circulation and perfusion of isolated body portions, e.g., limbs and organs, whether attached to the original body, detached and being preserved or prepared for transplant, or attached to a new body. It may also be used in laboratory animals, e.g. cats, dogs, rabbits, monkey and rats, for these purposes in order to develop new methods and techniques for organ and limb transplants.
  • the active compounds also exhibit some vasodilatory action on blood vessels and therefore have a utility as anti-hypertensives for the treatment of high blood pressure in mammals, including man.
  • the amount of active compound required for therapeutic or prophylactic effect will vary with the route of administration, and the nature of the condition under treatment.
  • a suitable dose for a mammal, including man, of active compound will lie in the range of 0.1 to 300 mg per kg body weight, particularly from 0.5 to 10 mg per kg body weight, for example 2 mg per kg.
  • a suitable single oral dose for an adult human lies within the range of 50 to 600 mg, for example 150 mg given say three times a day.
  • the formulations both for veterinary and for human medical use, of the present invention comprise an active compound as above defined, together with one or more acceptable carriers therefor and optionally other therapeutic ingredients.
  • the carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the references herein to pharmaceutical formulations do not include mere mixtures consisting of the active compound a non- sterile organic solvent or water.
  • Unit doses of a formulation may contain between 60 mg and 1.5 g of an active compound.
  • a tablet may contain 1-cyclooctylmethyl-imidazole or a pharmaceutically acceptable acid addition salt thereof in an amount of 50 to 500 mg based on the amount of imidazole base.
  • the formulations include those suitable for oral, rectal, vaginal or parenteral (including subcutaneous, intramuscular and intravenous) administration.
  • Preferred formulations include tablets, capsules and injectable suspensions or solutions.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound (in the form of the base or a pharmaceutically acceptable acid addition salt) with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active compound with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation.
  • Imidazole (2.0 g, 0.03 mol) was added to a solution of sodium (0.7 g, 0.03 mol) in dry ethanol (50 ml). The mixture was stirred and heated to boiling when bromomethylcyclooctane (5.5 g, 0.027 mol) was added dropwise. Following the addition, the reaction mixture was stirred and boiled for 15 h.
  • Imidazole (6.8 g, 0.1 mol) was added to a solution of sodium (2.3 g, 0.1 mol) in dry ethanol (100 ml). This solution was stirred and heated to reflux when bromomethylcyclopentane (16.3 g, 0.1 mol) was added dropwise. Following the addition, the mixture was stirred and heated under reflux for 1 6 h.
  • Imidazole (1.0 g, 0.0147 mol) was added to a solution of sodium (0.34 g, 0.0148 mol) in dry ethanol (30 ml). This solution was stirred and heated to boiling when 3-bromopropylcyclopentane (2.94 g, 0.0154 mol) was added dropwise. Following the addition, the reaction mixture was stirred and boiled for 20 h.
  • Bromomethylcycloheptane (5.3 g, 0.0278 mol) was added dropwise to a stirred solution of potassium t-butoxide (3.1 g, 0.0277 mol) and imidazole (1.9 g, 0.0279 mol) in dry n-butanol (50 ml) maintained at 100° and under dry nitrogen. After the additoin ( ⁇ 20 mins) the temperature of the reaction mixture was raised to boiling. The reaction mixture was then stirred and boiled for 7 h and then cooled.
  • the reaction mixture was treated with water (50 ml) and the organic layer separated.
  • the aqueous solution was extracted with petroleum ether (b.p. 40-60°,3 x 25 ml) and the organic layer and petroleum ether extracts combined, washed with 2M-sodium hydroxide solution (25 ml), and with water (25 ml), and then dried (MgS0 4 ). Concentration of the solution under reduced pressure gave an oil 2.3 g) which was distilled, b.p. 48 ⁇ 50°/0.25 mmHg (0,333 x 10- 8 Pa).
  • Horse platelets were prepared from whole horse blood by differential centrifugation. Approximately 10 6 platelets were homogenised in 1 ml 100 mM Tris buffer pH 7.4. Various concentrations of active compound were added and the reaction sets incubated for 5 minutes at ambient temperature. To each tube was added 20 nM of arachidonic acid containing 10 6 DPM of labelled arachidonic acid and the tubes incubated for 3 minutes at 37°C in a shaking water bath. After incubation the radioactive products were extracted from the acidified aqueous phase wieth ethyl acetate and after concentration resolved by thin layer chromotography on silica gel with chloroform/methanol/acetic acid/water (90:8:1:0.8) as a developing solvent. The amount of thromboxane produced was measured by scraping the radioactive zone corresponding to thromboxane B 2 and estimating the radioactivity in a liquid scintillation counter.
  • the selectivity of the active compounds was measured in a similar manner to that described above and the amount of PGE, PGF and PGD produced was determined. The greater the selectivity, the more of the prostaglandins are produced indicating lower inhibition of cyclo-oxygenase.
  • the imidazole salt is ground to a fine powder, blended with the starch and then the mixture granulated with an aqueous solution of the polyvinylpyrrolidone.
  • the granules are sieved 1000 ⁇ , dried, sieved again and the magnesium stearate added. The mixture is then compressed into tablets.
  • the lactose is blended with the starch.
  • Tablets (150 mg) of the imidazoles of Example 8 are prepared in the same manner from the following ingredients, except that the starch, pregelled starch and imidazole compound are all blended together prior to granulation:
  • Each 1 ml ampoule supplies 150 mg of the imidazole compound: 1-cyclooctylmethylimidazole fumarate.
  • Each 1 ml of solution provides 150 mg of the compound: 1-cyclooctylmethylimidazole fumarate.
  • Bromocycloheptane (10.0 g, 0.0565 mol) was added dropwise to a stirred, boiling mixture of imidazole (3.85 g, 0.0566 mol) and sodium bicarbonate (4.75 g, 0.0565 mol) in methanol. Following the addition, the reaction mixture was stirred and boiled for 24 h.
  • tablets were prepared of:
  • Injectable formulations were prepared by the method of the Injectable formulation in Example 12 above using the imidazoles mentioned in the immediately preceding Example.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

  • The present invention relates to imidazole derivatives and salts thereof, to their synthesis and intermediates therefor, to pharmaceutical formulations containing such compounds and to the use of these componds in medicine.
  • Thromboxane A2 (TXA,), a potent stimulator of blood platelet aggregation, is produced, in platelets, from the prostaglandin endoperoxides PGG2 and PGH2. Prostacyclin (PGI2), which has potent anti-aggregatory activity, is also produced (in blood vessel walls) from PGG2 and PGH2 and it has been suggested that a balance between the production of TXA2 and PGI2 is the controlling factor in thrombus formation. It would, in consequence, be desirable in the treatment and prophylaxis of thrombo-embolic disorders to be able to selectively inhibit TXA2 synthetase, thereby favouring the production of the anti-aggregatory agent PGI2.
  • Imidazole and 1-methylimidazole are known to provide some degree of inhibition of the enzymic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes (Moncada et al., Prostaglandins, 13/4, 611-618, 1977). Certain 1-(C10-19)hydrocarbyl-imidazoles have been described as being capable of lowering serum cholesterol levels (U.K. Patent No. 1 364 312; Biochem. Pharmacol. 24, 1902-1903, 1975).
  • Also 1-cyclohexylmethyl-imidazole is disclosed in Wiss. Z.Univ. Halle, Math-Nat. XI/5, pages 603-612, although no physiological activity is ascribed therein to the compound.
  • German Auslegeschrift 1213413 describes a process for the preparation of a broad class of 1- alkenyl and 1-alkylimidazoles optionally substituted by alkyl groups in the 2,3- and/or 5-positions. The resulting imidazoles are described in the specification as being useful as intermediates for the preparation of pest control and textile treatment agents.
  • The inhibitory potency of several derivatives of imidazole and 1-substituted imidazoles, such as 1-methylimidazole on thromboxane synthetase is known from Biochemical and Biophysical Research Communications, Vol. 80, No. 1 (1978), 236-242. The authors of this article report that the inhibitory potency of 1-substituted imidazoles is increased with increasing chain length, and state that 1-nonyl- imidazole and 1-(2-isopropylphenyl)imidazole were found to possess the highest potency. The best activities are obtained with compounds wherein the 1-substituent on the imidazole ring is a straight chain alkyl group. The reference gives no information as to the 1-substituted imidazoles carrying cycloalkyl or cycloalkenyl groups of 4 to 9 carbon atoms or alkyl radicals of from 4 to 7 carbon atoms or alkenyl or alkynyl radicals of from 4 to 9 carbon atoms.
  • We have now discovered that TXA2 synthetase may be inhibited by 1-substituted imidazoles of formula (I) and pharmaceutically acceptable acid addition salts thereof. The compounds of formula (I) and their salts are hereinafter referred to as the "active compounds".
  • The compounds of formula (1) are:-
    Figure imgb0001
    in which A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of from 1 to 3 carbon atoms, n is 0 or 1, and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9, preferably from 5 to 8, carbon atoms and optionally substituted by one, two, three or more alkyl radicals each containing from 1 to 4 carbon atoms, or, when n is 1, A and R together form a straight-chain alkyl radical of from 4 to 7 carbon atoms or an alkenyl or alkynyl group of from 4 to 9 carbon atoms.
  • A novel class of compounds within the scope of formula (I) are those of formula (la):
    Figure imgb0002
    in which A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of from 1 to 3 carbon atoms and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9, preferably from 5 to 8, carbon atoms and optionally substituted by one or more alkyl radical each containing from 1 to 4 carbon atoms, with the proviso that when A is a methylene radical, R is not unsubstituted cyclohexyl. These compounds are described and claimed in our copending Application 78100753.9 (specification 0000951A1 ).
  • The following classes of compounds within the scope of formula (I) are also new and constitute features of the present invention:-
    • a) compounds of formula (I) wherein (A)n and R together form an alkenyl radical of from 5 to 9 carbon atoms.
    • b) compounds of formula (I) wherein n is 0 and R is a cycloalkyl or cycloalkenyl group of from 4 to 9 carbon atoms, optionally substituted by one or more alkyl radicals each containing 1 to 4 carbon atoms, with the proviso that R is not unsubstituted cyclohexyl, and is also, preferably, not substituted cyclohexyl.
  • In formula (I) and (la) examples of cycloalkyl radicals are cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl; cycloalkenyl radicals include cyclohex-3-enyl, cyclopentyl, and 1,4-cyclohexadienyl; alkenyl radicals include pent-2-enyl and pent-4-enyl.
  • A valuable class of compounds of formula (I) are those in which n is 1, R is cyclohexyl, cyclohexyl, cycloheptyl, cyclooctyl, or cycloalkenyl of 6 to 8 carbon atoms, and A is -cH2 or ―(CW2)2―. Compounds of formula (I) or (la) may also be used pharmaceutically acceptable acid addition salts. Especially preferred compounds include:
    • 1-Cyclooctylmethylimidazole
    • 1-Cyclohex-3-enylmethylimidazole
    • 1-Cyclohexylethylimidazole
    • 1-Cycloheptylmethylimidazole

    and pharmaceutically acceptable acid additions salts thereof
  • Other preferred compounds include:
    • 1-Cyclopentylmethylimidazole
    • 1-Cyclooctylvinylimidazole
    • 1-( 1-Cyclooctylethyl)imidazole
    • 1-(2-Cyclooctylethyl)imidazole
    • 1-(3-Cyclooctylpropyl)imidazole
    • 1-(Cyclohept-2-enylmethyl)imidazole
    • 1-Cyclononylmethylimidazole
    • 1-(4-Methylcyclohexylmethyl)imidazole
    • 1-(Cyclobutylmethyl)imidazole
    • 1-Cycloheptylimidazole
    • 1-Cyclopentylimidazole
    • 1-Cyclohexylmethylimidazole
    • 1-n-Butylimidazole
    • 1-n-Pentylimidazole
    • 1-n-Hexylimidazole
    • 1-Pent-2-enylimidazole
    • 1-Pent-4-enylimidazole
    • 1-(3-Methylbutyl)imidazole

    and pharmaceutically acceptable acid addition salts thereof.
  • In contrast to imidazole and 1-methylimidazole the compounds of formula (I) are more potent inhibitors of TXA2 synthetase. Many of the compounds (for example in (I) R is cycloalkyl or cycloalkenyl, n is 1, and A is -CH2- or -(CH2)2- are also more selective in their action in not inhibiting other prostaglandin-generating enzymes such as cyclo-oxygenase. The compounds of formula (I) also do not produce the side-effects found with imidazole upon in vivo administration. The compounds of formula (I) are further capable of inhibiting platelet aggregation in vivo and also are capable of disaggregating platelet clumps. The compounds 1-cyclooctylmethylimidazole, 1-cyclohex-3-enylmethylimidazole and 1-cyclohexylethylimidazole and their salts especially displaying these properties.
  • Imidazoles of formula (I) and acid addition salts thereof may be made by any method known in the art for the synthesis of compounds of analogous structure. In general these methods comprise linking the imidazole ring to the remainder of the molecule; converting a precursor molecule by elimination of a functional group from the imidazole ring; and formation of the desired compound from a corresponding imidazoline, pyrazole or unsaturated analogue.
  • A most convenient method of synthesis involves the reaction of imidazole (formula II) or a salt thereof with an alkylating agent of formula (III):
    Figure imgb0003
    wherein R and A are as defined in formula (I) and Z is a leaving group. This reacion is well established in the literature, and the leaving group may be chosen from a variety of substituents but especially halo, preferably chloro or bromo, or from p-toluenesulphonyloxy but other arylsulphonyloxy, alkane- sulphonyloxy or aralkylsulphonyloxy radicals may be used. The reaction is preferably performed in the presence of an acid acceptor, for example an alkali metal alkoxide such as sodium methoxide or potassium tertiary butoxide in the presence of a corresponding alkanol. The leaving group Z may itself be formed in situ from the corresponding alkanol (Z= OH) by reaction with a hydrohalogenic acid (e.g. hydrochloric acid or a Lewis acid such as aluminium chloride: see Japanese Patent Kokai No. 131577/77) and the resulting agent of formula (III) reacted directly with imidazole without prior isolation. Alternatively an alkanol (Z= OH) or a derivative thereof (e.g. Z = R-A-O-) may be reacted directly with imidazole (II) by heating in the presence of a dehydrating agent such as phosphate acid, or a phosphate (see Japanese Patent Publication No. 5 1 105 060), sulphuric acid or sulphates (see Japanese Patent Publication No. 5 1 105 061 ).
  • Among precursor molecules which may be converted to a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof, are substituted imidazole derivatives of formula (IV) or addition salts thereof
    Figure imgb0004
    wherein A and R are as defined in formula (I), and Q1, Q2 and Q3 are the same or different, at least one being selected from thio (-SH), alkylthio (-Salkyl wherein alkyl has 1 to 4 carbon atoms) and halo preferably chloro or bromo, the remaining radical or radicals being selected from a radical having the same function or from hydrogen. The reaction conditions are chosen according to the nature of the radicals Q1, Q2 and Q3. Desulphurisation may be performed by oxidative or reductive procedures using for example nitric acid or Raney nickel; and reductive dehalogenation by the use of zinc and acetic acid or Raney nickel or other reagents known in the literature.
  • Another class of examples include carboxyimidazoles or derivatives thereof of formula (VI):
    Figure imgb0005
    wherein A and R are as defined in formula (I), at least one of R1, R2 and R4 is carboxyl or a derivative thereof (for example an ester such as an alkyl ester, an acid halide such as the chloride, or the nitrile) and the other(s) is hydrogen or carboxyl or a derivative as described. The compounds of formula (VI) may be converted into the imidazoles of formula (I) by any suitable decarboxylation conditions which may simply comprise heating the compounds with or without a catalyst such as copper.
  • The imidazoles of formula (I) may also be made a compound of formula (VII):
    Figure imgb0006
    is 1-imidazolidine, 1-imidazole or 1-pyrazole, A is a straight or branched saturated or unsaturated acyclic hydrocarbon radical, and R3 is a cycloalkyl or cycloalkenyl radical of from 4 to 9 carbon atoms optionally substituted by alkyl as defined in formula (I), provided that at least one of
    Figure imgb0007
    A1 and R3 is other than 1-imidazole, a saturated acyclic hydrocarbon and an optionally substituted cycloalkyl group respectively as defined in formula (I). Thus an imidazoline (VIII):
    Figure imgb0008
    wherein one of--- - represents an extra bond and A and R are defined in formula (I) may be dehydrogenated to the corresponding imidazole in the presence of a catalyst for example by heating to 250°C in the presence of palladium, nickel or platinum under pressure, or by heating with a dehydrogenating agent such as selenium or copper oxide. The 1-pyrazole compounds (VII) may be treated with ultra-violet irradiation, optionally under an inert atmosphere (e.g. argon) in for example 1,2-dimethoxyethane at room or elevated temperatures (see for example "Ring Transformations of Heterocycles" edited van der Plas, Academic Press, 1973 at page 261). The unsaturated imidazoles of formula (I) (in formula (VII), A and/or R3 are unsaturated) may be reduced to the corresponding saturated compounds with a noble metal catalyst, for example platinum or palladium in alkanol.
  • The intermediates for use in the above described reactions may also be made by conventional methods known in the art. Thus the 1-pyrazole and 1-imidazoline intermediates (formula (VII) may be prepared by alkylation of pyrazole and imidazoline in an analogous manner to that described above for preparation of the corresponding imidazoles. The intermediates of formula (III) may be made in known manner preferably by halogenation of the corresponding alcohols (formula (III). Z = -OH) where in such compounds R is cycloalkenyl; the alcohol is conveniently prepared by the Prins reaction from the cycloalkene and paraformaldehyde (Bull. Chem. Soc. Japan 46/8, 2512-5, 1973). The substituted imidazole intermediates of formula (IV) may be made in known manner, for example see "Imidazole and its derivatives" Part I. Ed. K. Hofmann, Interscience Publishers In. New York, 1973. For example the 2-thioimidazoles of formula (IV) may be made by cyciisation of an acetal of formula (IX):
    Figure imgb0009
    with thiocyanate, wherein R5 is alkyl.
  • The pharmaceutically acceptable addition salts of the compounds of formula (I) may be prepared by any method known in the art. In particular they may be prepared by treating the parent imidazole with the appropriate acid.
  • Examples of the addition salts of the compounds of formula (I) include those salts derived from the following acids: oxalic, hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salycyclic, succinic, toluene-p-sulphonic, tartaric, acetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic and benzene-sulphonic.
  • The imidazoles of formula (I) may be used in conjunction with a phosphodiesterase inhibitor, which provides a further, synergistic increase in effect, as it acts against platelet aggregation by a different pathway.
  • Suitable phosphodiesterase inhibitors for use in potentiating the anti-aggregatory effects of the active compounds include as such or as pharmaceutically acceptable salts:-
    • (a) Xanthine derivatives such as:-
      • Theophylline(3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione), and salts thereof. 3-Isobutyl-1-methyl-xanthine;
      • Caffeine(3,7-dihvdro-1,3,7-trirnethyl-1H-purine-2,6-dione) and salts thereof; and
      • Aminophylline (adduct of Theophylline and 1,2-ethanediamine (2:1)).
    • (b) Isoquinoline derivatives, for example:-
      • Papaverine(1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline) and salts thereof; and
      • 6,7-Diethoxy-l-(4,5-diethoxybenzyl)isoquinoline or its salts e.g. its hydrochloride;
    • (c) Derivatives of pyrimido(5,4-d)-pyrimidine, for example:-
      • Dipyridamole(2,2',2",2'"-(4,8-dipiperidinopyrimido[5,4-d]pyrimidin-2,6-dlylnitrilo)tetraethanol) and its salts;
      • 2,2',2",2"'-[[4-(1-piperidinyl)pyrimido[5,4-d]pyrimidin-2,6-diyl]dinitrilo]tetrakisethanol and its salts; and
      • 2,4,6-tri-4-morpholinylpyrimido[5,4-d]pyrimidine and its salts.
    • (d) Derivatives of thieno[3,2-d]pyrimidine, for example:-
      • N-[4-(4-morpholinyl)thieno]3,2-d[pyrimidin-2-yl]-1,2-ethanediamine.
    • (e) Derivatives of pyrazolo[3',4':2,3]pyrido[4,5-b] [1,5]benzodiazepin-6-(3H)-one, for example:-
      • 3-Ethyl-7,12-dihydro-7,12-dimethylpyrazolo[4',3':5,6]pyrido[4,3-b]-[1,5]benzodiazepin-6-(3H)-one;
      • 3-Ethyl-7,12-dihydro-9-methoxy-7,12-dimethylpyrazolo[3',4':2,3]pyridoL4,5-b][1,5]benzo- diazepin-6-(3H)-one; and
      • 10-Chloro-3-ethyl-7,12-dimethyl-7,12-dihydropyrazolo[4',3':5,6]pyrido[4,3-
    • b] [1,5]benzodiazepin-6-(3H)-one.
    • (f) Derivatives of 1H- or 2H-pyrazolo[3,4-b]pyridine, for example:-
      • 4-(Butylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester;
      • 4-(Butylamino)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid ethyl ester;
      • 4-Chloro-1-ethyl-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-acetonitrile;
      • 1-Ethyl-4-(isopropylidenehydrazino)-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester or its salts such as its hydrochloride hemihydrate; and
      • 2-Methyl-6-phenyl-4-(1-piperidinyll-2H-pyrazolo[3,4-b]pyridine or its salts e.g. its hydrochloride.
    • (g) Derivatives of 5H-furo-[3,4-elpyrazolo|3,4-b|pyridine-5-one, for example:-
      • 4-(Butylamino)-1-ethyl-1,7-dihydro-7-hydroxy-5H-furo-[3,4-e]pyrazolo[3,4-b]pyridine-5-one; and
    • (h) Derivatives of 1 (2H)-naphthalenone, for example:-
      • 2[(Dimethylamino)methyl]-3,4-dihydro-7-methoxy-1 (2H)-naphthalenone or its salts e.g. its 1:1 hydrochloride.
  • The active compounds are particularly useful in the treatment and/or prophylaxis of thrombo-embolic disorders in mammals, including man. It is to be understood that the term "thrombo-embolic disorders" includes those disorders whose etiology is associated with platelet aggregation.
  • The active compounds are useful wherever it is desired to inhibit platelet aggregation and/or to reduce the adhesive character of platelets, and consequently to treat or prevent the formation of thrombi in mammals, including man. For example, the compounds are useful in the treatment and prevention of myocardial infarcts cerebro-vascular thrombosis and ischaemic peripheral vascular disease; to treat and prevent post-operative thrombosis; and to promote patency of vascular grafts following surgery.
  • The active compounds are also useful as an addition to blood, blood products, blood substitutes, and other fluids which are used in artificial extra-corporeal circulation and perfusion of isolated body portions, e.g., limbs and organs, whether attached to the original body, detached and being preserved or prepared for transplant, or attached to a new body. It may also be used in laboratory animals, e.g. cats, dogs, rabbits, monkey and rats, for these purposes in order to develop new methods and techniques for organ and limb transplants.
  • The active compounds also exhibit some vasodilatory action on blood vessels and therefore have a utility as anti-hypertensives for the treatment of high blood pressure in mammals, including man.
  • The amount of active compound required for therapeutic or prophylactic effect will vary with the route of administration, and the nature of the condition under treatment. In general a suitable dose for a mammal, including man, of active compound will lie in the range of 0.1 to 300 mg per kg body weight, particularly from 0.5 to 10 mg per kg body weight, for example 2 mg per kg. A suitable single oral dose for an adult human lies within the range of 50 to 600 mg, for example 150 mg given say three times a day.
  • While it is possible for the active compounds to be administered as the raw chemical it is preferable to present them as a pharmaceutical formulation. The formulations, both for veterinary and for human medical use, of the present invention comprise an active compound as above defined, together with one or more acceptable carriers therefor and optionally other therapeutic ingredients. The carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. It should be noted that the references herein to pharmaceutical formulations do not include mere mixtures consisting of the active compound a non- sterile organic solvent or water. Unit doses of a formulation may contain between 60 mg and 1.5 g of an active compound. For example, a tablet may contain 1-cyclooctylmethyl-imidazole or a pharmaceutically acceptable acid addition salt thereof in an amount of 50 to 500 mg based on the amount of imidazole base.
  • The formulations include those suitable for oral, rectal, vaginal or parenteral (including subcutaneous, intramuscular and intravenous) administration. Preferred formulations include tablets, capsules and injectable suspensions or solutions.
  • The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound (in the form of the base or a pharmaceutically acceptable acid addition salt) with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active compound with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation.
  • The following Examples are provided by way of an illustration of the present invention and should in no way be construed as constituting a limitation thereof. All temperatures are given in degrees Celsius.
    • Example 1 1-Cyclooctylmethylimidazole
  • Imidazole (2.0 g, 0.03 mol) was added to a solution of sodium (0.7 g, 0.03 mol) in dry ethanol (50 ml). The mixture was stirred and heated to boiling when bromomethylcyclooctane (5.5 g, 0.027 mol) was added dropwise. Following the addition, the reaction mixture was stirred and boiled for 15 h.
  • After cooling, the reaction mixture was filtered, and the filtrate concentrated under reduced pressure. The residue was dissolved in 2M-hydrochloric acid (100 ml) and the solution washed with ether (25 ml). The aqueous layer was basified with 10M-sodium hydroxide solution and then extracted with chloroform (3 x 50 ml). The chloroform extracts were combined and dried (MgS04). Evaporation of the chloroform gave an oil which was purified using a silical gel column and elution with ethyl acetate/methanol (9:1). The product was further purified by distillation, b.p. 120-1220/0.2 mmHg.*. By the method described in example 1 above the following compounds were prepared:
    • (a) 1-cyclooctylvinylimidazole
    • (b) 1-(2-cyclooctylethyl)imidazole
    • (c) 1, 1-cyclooctyl)ethylimidazol
    • (d) 1-(3-cyclooctylpropyl)imidazole
    • (e) 1-(3-methylcyclohept-2-enylmethyl)imidazole
    • (f) 1-(3-methylcycloheptylmethyl)imidazole
    • (g) 1-(cyclohex-3-enylmethyl)-imidazole m.p. 36-37 degrees
    • (h) 1-(2-cyclohexylethyl)imidazole b.p. 148-150 degree 95-96 degrees/0.2 mm (0,267 x 10-8 Pa)
    • (i) 1-cyclobutylmethylimidazole b.p. 148-150 degrees/25 mm (33,325 x 10-8 Pa)
    Example 2 Preparation of 1-cyclopentylmethylimidazole
  • Imidazole (6.8 g, 0.1 mol) was added to a solution of sodium (2.3 g, 0.1 mol) in dry ethanol (100 ml). This solution was stirred and heated to reflux when bromomethylcyclopentane (16.3 g, 0.1 mol) was added dropwise. Following the addition, the mixture was stirred and heated under reflux for 1 6 h.
  • After cooling, the reaction mixture was filtered and the filtrate concentrated under pressure. The residue was dissolved in 2M-hydrochloric acid (150 ml) and the solution washed with ether. The aqueous solution was basified with 10M-sodium hydroxide solution, and the product extracted with chloroform (3 x 50 ml). The extracts were combined, dried (MgS04), and the solution concentrated to afford a yellow oil.
  • The oil was purified using a silica gel column and elution with ethyl acetate/methanol (9:1). The product fractions were combined and concentrated under reduced pressure to afford 1-cyclopentylmethylimidazole (1.9 g), which was further purified by distillation, b.p. 68―69°/0.125 mmHg (0,167 x 10-8 Pa).
    • Example 3 Preparation of 1-(3-cyclopentylpropyl)imidazole
  • Imidazole (1.0 g, 0.0147 mol) was added to a solution of sodium (0.34 g, 0.0148 mol) in dry ethanol (30 ml). This solution was stirred and heated to boiling when 3-bromopropylcyclopentane (2.94 g, 0.0154 mol) was added dropwise. Following the addition, the reaction mixture was stirred and boiled for 20 h.
  • After cooling, the mixture was filtered and the filtrate concentrated under reduced pressure. The residue was dissolved in 2M-hydrochloric acid (50 ml) and the solution washed with ether (25 ml). The acid solution was then basified with 10M-sodium hydroxide solution, and the product extracted with chloroform (3 x 25 ml). The combined extracts were dried (MgS04) and concentrated under reduced pressure to afford a yellow oil (2.1 g).
  • The oil was purified by column chromatography (silica gel) using ethyl acetate/methanol (9:1) as eluent. The product fractions were combined and concentrated to afford 1-(3-cyclopentylpropyl)imidazole which was further purified by distillation, b.p. 89―90°/0.1 mmHg (0,133 x 10-8Pa).
    • Example 4 Preparation of 1-(cycloheptylmethyllimidazole
  • Bromomethylcycloheptane (5.3 g, 0.0278 mol) was added dropwise to a stirred solution of potassium t-butoxide (3.1 g, 0.0277 mol) and imidazole (1.9 g, 0.0279 mol) in dry n-butanol (50 ml) maintained at 100° and under dry nitrogen. After the additoin (~20 mins) the temperature of the reaction mixture was raised to boiling. The reaction mixture was then stirred and boiled for 7 h and then cooled.
  • The mixture was filtered, and the n-butanol was removed under reduced pressure to give a pale yellow oil. The oil was dissolved in 2M-hydrochoric acid (100 ml) and the acid solution was washed with ether (100 ml) and then basified with 10M-sodium hydroxide solution and the resulting suspension was extracted with chloroform (3 x 50 ml). The chloroform extracts were combined, dried (MgS04), and concentrated under reduced pressure to give a pale yellow oil.
  • The oil was purified using a silica gel column and elution with ethyl acetate/methanol (9:1). Concentration of the fractions containing 1-(cycloheptylmethyl)imidazole gave a pale yellow oil which was further purified by distillation, b.p. 92-94°/0.1 mmHg (0,133 x 10-8 Pa).
    • Example 5 Preparation of 1-(2-cyclooctenylmethyl)imidazole (a) Preparation of 2-cyclooctene-1-methanol using the Prins reaction (Uchida et al., Bull. Chem. Soc., Japan, 1973, 46, 2512)
  • Cyclooctene (69.0 g, 0.63 mol) was added dropwise, to a stirred suspension of paraformaldehyde (24.0 g) in 98% formic acid (100 ml). After the addition, the reaction mixture was stirred and heated under reflux for 2 h. Water (100 ml) was then added, and the aqueous solution was extracted with ether (50 ml). The ether solution was washed with saturated sodium bicarbonate solution (5 x 50 ml), with water (2 x 50 ml), and dried (MgS04). Concentration under reduced pressure afforded a brown oil which was purified by distillation, the fraction b.p. 80-1 10°/24 mmHg (31,992 x 10-8 Pa) being retained.
  • A portion of the aforesaid oil (10 g) was treated with Claisen's alkali [potassium hydroxide (10 g), methanol (31.2 ml) and water (8 ml)], and the reaction mixture was then boiled for 2 h.
  • After cooling, the mixture was poured onto iced-water (50 ml) and extracted with ether (3 x 50 ml). The ether extracts were combined and dried (MgS04). Concentration of the solution under reduced pressure afforded an oil which was distilled, to afford 2-cyclooctene-1-methanol, b.p. 128-130°/23 mmHg (30,659 x 10-8 Pa).
    • (b) Preparation of 2-cyclooctene-1-bromomethane
  • A solution of phosphorus tribromide (1.02 ml, 0.0105 mol) in petroleum ether (b.p. 40-60°, 5 ml) was added dropwise to a stirred solution of 2-cyclooctene-1-methanol (2.8 g, 0.02 mol) and dry pyridine (0.104 g, 0.0013 mol) in petroleum ether (b.p. 40-60°; 15 ml) at -10°. After the addition, the reaction mixture was set aside at ambient temperature for 48 h.
  • The reaction mixture was treated with water (50 ml) and the organic layer separated. The aqueous solution was extracted with petroleum ether (b.p. 40-60°,3 x 25 ml) and the organic layer and petroleum ether extracts combined, washed with 2M-sodium hydroxide solution (25 ml), and with water (25 ml), and then dried (MgS04). Concentration of the solution under reduced pressure gave an oil 2.3 g) which was distilled, b.p. 48―50°/0.25 mmHg (0,333 x 10-8 Pa).
    • (c) Preparation of 1-(2-cyclooctenylmethyl)imidazole
  • 2-Cyclooctene-1-bromomethane (0.7 g, 0.0034 mol) was added dropwise to a boiling solution of imidazole (0.24 g, 0.0035 mol) and potassium t-butoxide (0.39 g, 0.0035 mol) in dry n-butanol, under dry nitrogen. After the addition, the reaction mixture was stirred and heated under reflux for 1 h. The pure product was obtained as described in Example 4, b.p. 108-110°/0.02 mmHg (0,0267 x 10-8 Pa).
    • Example 6 Preparation of 1-(4-methylcyclohexylmethyl)imidazole
  • 1-Bromomethyl-4-methylcyclohexane (3.1 g, 0.0162 mol) was added dropwise to a stirred, boiling solution of imidazole (1.12 g, 0.0165 mol) and potassium t-butoxide (1.85 g, 0.0165 mol) in dry n-butanol, under dry nitrogen. After the addition, the reaction mixture was stirred and heated under reflux for 10 h.
  • After cooling, the reaction mixture was filtered, and then concentrated under reduced pressure. The residue was dissolved in 2M-hydrochloric acid (100 ml) and the solution was washed with ether (50 ml). The acid solution was basified with 10M-sodium hydroxide solution and extracted with chloroform (3 x 50 ml). The combined chloroform extracts were dried (MgS04) and then concentrated under reduced pressure. The oily residue was purified using a silica gel column and elution with ethyl acetate/methanol (9:1). The fractions containing 1-(4-methylcyclohexylmethyl)imidazole were combined, concentrated, and the resulting oil distilled, b.p. 801/0.125 mmHg (0,167 x 10-8 Pa).
    • Example 7 Biological Results
  • Horse platelets were prepared from whole horse blood by differential centrifugation. Approximately 106 platelets were homogenised in 1 ml 100 mM Tris buffer pH 7.4. Various concentrations of active compound were added and the reaction sets incubated for 5 minutes at ambient temperature. To each tube was added 20 nM of arachidonic acid containing 106 DPM of labelled arachidonic acid and the tubes incubated for 3 minutes at 37°C in a shaking water bath. After incubation the radioactive products were extracted from the acidified aqueous phase wieth ethyl acetate and after concentration resolved by thin layer chromotography on silica gel with chloroform/methanol/acetic acid/water (90:8:1:0.8) as a developing solvent. The amount of thromboxane produced was measured by scraping the radioactive zone corresponding to thromboxane B2 and estimating the radioactivity in a liquid scintillation counter.
  • The concentration of active compound to reduce the enzyme activity by 50% (ED50) was established. The results are shown in Table A.
  • The selectivity of the active compounds was measured in a similar manner to that described above and the amount of PGE, PGF and PGD produced was determined. The greater the selectivity, the more of the prostaglandins are produced indicating lower inhibition of cyclo-oxygenase.
  • The ED50 and Selectivity results are shown in Table A in which 0 indicates no selectivity; + low selectivity; ++ medium selectivity; and +++ high selectivity; ++++ exceptionally high selectivity.
    Figure imgb0010
    • Example 8
  • Figure imgb0011
  • The imidazole salt is ground to a fine powder, blended with the starch and then the mixture granulated with an aqueous solution of the polyvinylpyrrolidone. The granules are sieved 1000 µ, dried, sieved again and the magnesium stearate added. The mixture is then compressed into tablets.
  • In the same manner, tablets of 1-cyclohex-3-enylmethylimidazole and 1-cyclohexylethyl- imidazole are prepared.
    • Example 9 Tablet formulation
  • Tablets (150 mg) of the imidazoles described in the preceding example are prepared as in the same manner from the following ingredients:
    Figure imgb0012
  • In the preparation, the lactose is blended with the starch.
    • Example 10 Tablet formulation
  • Tablets (100 mg) of the imidazoles of Example 8 are prepared in the same manner from the following ingredients:
    Figure imgb0013
    • Example 11 Tablet formulation
  • Tablets (150 mg) of the imidazoles of Example 8 are prepared in the same manner from the following ingredients, except that the starch, pregelled starch and imidazole compound are all blended together prior to granulation:
    Figure imgb0014
    • Example 12 Injectable formulation
  • Figure imgb0015
  • Suspend the compound in 4 of the available quantity of water. Add sufficient Lactic Acid to dissolve the compound and to reduce the pH to 3.0. Dilute to volume with Water for Injections.
  • Sterilise the solution by passage through a membrane filter, pore size 0.22 µm.
  • Distribute the solution using aseptic precautions into sterilised ampoules, 1 ml per ampoule. Seal by fusion of the glass.
  • Each 1 ml ampoule supplies 150 mg of the imidazole compound: 1-cyclooctylmethylimidazole fumarate.
    • Example 13 Injectable formulation
  • Figure imgb0016
  • Suspend the compound in ½ the final volume of Water for Injections. Add sufficient Citric Acid as a 10% solution in Water for Injections to dissolve the compound and reduce the pH to 3.0. Dilute to volume with Water for Injections.
  • Sterilise the solution by passage through a membrane filter, pore size 0.22 µm.
  • Distribute the solution with aseptic precautions into sterilised vials, 25 ml per vial. Stopper with sterile rubber closures and seal with an aluminium cap.
  • Each 1 ml of solution provides 150 mg of the compound: 1-cyclooctylmethylimidazole fumarate.
    • Example 14 Injectable formulation
  • In the manner described in the preceding two Examples, injectable formulations of 1-cyclohexylethylimidazole and 1-cyclohex-3-enylmethylimidazole salts were prepared.
    • Example 15 (a) 1-n-Butylimidazole
  • 1-Bromobutane (27.4 ml, 0.255 mol) was added dropwise to a stirred solution of imidazole (13.6 g, 0.2 mol) in a mixture of methanol (30 ml) (30 ml) and 10M-sodium hydroxide solution (30 ml) maintained at 30-40°. Following the addition, the reaction mixture was stirred and heated under reflux for 12 h.
  • After concentration under reduced pressure, the residue was extracted with chloroform (2 x 50 ml) and the extracts were combined and dried (MgS04). Concentration of the extracts under reduced pressure gave a yellow oil which was purified using a silica gel column and ethyl acetate/methanol (9:1) as eluent. The product fractions were combined, concentrated, and the resulting oil distilled to afford 1-n-butylimidazole, b.p. 122-123°/20 mm Hg (26,666 x 10-8 Pa).
    • (b) 1-n-Butylimidazole oxalate
  • To 1-n-butylimidazole (0.31 g, 0.0025 mol) in methanol (5 ml) was added oxalic acid (0.225 g, 0.0025 mol) in methanol (5 ml). After heating under reflux for 5 minutes, the mixture was evaporated under reduced pressure to afford a white solid. Recrystallisation of the solid from ethanol/ether (1:4) afforded 1-n-butylimidazole oxalate as colourless needles, m.p. 82―83°.
    • (c) 1-n-Butylimidazole perchlorate
  • To 1-n-butylimidazole (0.31 g, 0.0025 mol) in methanol (5 ml) was added perchloric acid (0.33 g, 70%) in methanol (3 mi). After boiling for 5 minutes, the mixture was evaporated under reduced pressure to afford a white solid. Recrystallisation of the solid from ethyl acetate/ether (1 :4) afforded 1-n-butylimidazole perchlorate as a white solid, m.p. 54-55°.
    • Example 16 6
  • By the method described in Example 15 above the following compound was prepared:-
    • 1-(3-Methylbutyl)imidazole, b.p. 62―64°/0.2 mmHg (0,2666 x 10-8 Pa). In place of sodium hydroxide, sodium bicarbonate was used.
    Example 17 1-But-2-enylimidazole (1-crotylimidazole)
  • 1-Chlorobut-2-ene (3.2 g, 0.035 mol) in methanol (35 ml) was added dropwise to a stirred, boiling mixture of imidazole (11.9 g, 0.175 mol) and sodium bicarbonate (2.95 g, 0.035 mol) in methanol (35 ml). After the addition, the reaction mixture was stirred and boiled for 24 hr.
  • After cooling, the reaction mixture was filtered, and the solution concentrated under reduced pressure. The residue was dissolved in water (60 ml) and the product extracted with chloroform (3 x 20 ml). The combined chloroform extracts were washed with saturated brine (25 ml), dried (MgSO4), and then concentrated under reduced pressure. Distillation of the resulting oil gave 1-but-2-enylimidazole as a colourless oil, b.p. 123-124°/18 mmHg (23,994 x 10-8 Pa).
    • Example 18 (a) 1-n-Pentylimidazole (1-n-Amylimidazole)
  • 1-n-Bromopentane (30.0 ml, 0.24 mol) was added dropwise to a stirred solution of imidazole (13.6 g, 0.2 mol) in methanol (30 ml) and 10M-sodium hydroxide (30 ml). Following the addition, the reaction mixture was stirred and heated under reflux for 24 h.
  • After cooling, the solution was concentrated under reduced pressure and the residue extracted with chloroform (2 x 50 ml). The chloroform extracts were combined, dried (MgSO4), and concentrated to afford a yellow oil which on distillation gave 1-n-pentylimidazole, b.p. 66-681/0.15 mmHg.
    • (b) By the method described in (a) the following compound was prepared:-
  • 1-n-Hexylimidazole, b.p. 78―80°/0.2 mmHg (0,2666 x 10-8 Pa).
    • Example 19 1-Cyclohexylmethylimidazole
  • Bromomethylcyclohexane (39.8 g, 0.225 mol) was added dropwise to a stirred, boiling solution of imidazole (13.6 g, 0.2 mol) and sodium (4.6 g, 0.2 mol) in dry ethanol (100 ml). Following the addition, the reaction mixture was stirred and boiled for 5 h.
  • After cooling, the reaction mixture was filtered, and the filtrate concentrated under reduced pressure. The residue was dissolved in water (150 ml), washed with ether (50 ml), and the product extracted with chloroform (3 x 50 mi). The combined chloroform extracts were dried (MgS04) and concentrated to give a yellow oil. Distillation of the oil gave 1-cyclohexylmethylimidazole, b.p. 86―90°/0.2 mmHg (0,2666 x 10-8 Pa) m.p. 27-30°.
    • Example 20 1-Cycloheptylimidazole
  • Bromocycloheptane (10.0 g, 0.0565 mol) was added dropwise to a stirred, boiling mixture of imidazole (3.85 g, 0.0566 mol) and sodium bicarbonate (4.75 g, 0.0565 mol) in methanol. Following the addition, the reaction mixture was stirred and boiled for 24 h.
  • After cooling, the mixture was concentrated under reduced pressure. The residue was dissolved in 2M-hydrochloric acid (150 ml), and this solution was washed with ether (50 ml). The acid solution was basified with 10M-sodium hydroxide solution, and then extracted with chloroform (3 x 50 ml). The combined extracts were dried (MgSO4) and then concentrated. The resulting oil was purified on a silica gel column and elution with ethyl acetate/methanol (9:1). The product fractions were pooled, concentrated, and the resulting oil was distilled, b.p. 102-104°/0.15 mmHg (0,19995 x 10-8 Pa) m.p; 31-35°.
    • Example 21 Preparation of 1-cyclopentylimidazole
  • To a stirred soluton of imidazole (6.8 g, 0.1 mol) in dry dimethylformamide (100 ml), under dry nitrogen, was added sodium hydride (4.8 g, 50% dispension in oil, 0.1 mol) portionwise. After the addition, the reaction mixture was stirred for 0.25 h when bromocyclopentane (14.9 g, 0.1 mol) in dry dimethylformamide (100 ml) was added dropwise. The reaction mixture was then stirred at ambient temperature for 1 h, after which it was poured onto an equal volume of water and this mixture was shaken well. The product was extracted with chloroform (3 x 200 ml) and the extracts combined and dried (MgSO4). The solution was concentrated under reduced pressure to afford a yellow oil. Purification by chromatography on silica gel and elution with methanol/ethyl acetate (1:9) followed by distillation gave the product, b.p. 67―68°/0.2 mm (0,2666 x 10-8 Pa).
    • Example 22 Preparation of 1-pent-2-enylimidazole
  • 1-Bromopent-2-ene (18.5 g, 0.124 mol) was added dropwise to a stirred, boiling mixture of imidazole (10.0 g, 0.147 mol) and sodium bicarbonate (12.4 g, 0.015 mol) in dry methanol (50 ml). Following the addition, the mixture was stirred and heated under reflux for 24 h.
  • After cooling, the reaction mixture was filtered and the filtrate concentrated under reduced pressure. The residue was dissolved in 2M-hydrochloric acid and this solution was washed with ether. The acid solution was basified with 1 OM-sodium hydroxide solution and the product was extracted with chloroform (3 x 50 ml). The combined extracts were dried (MgS04) and then concentrated to afford an oil which was purified on a silica gel column by elution with ethyl acetate/methanol (9:1). The product fractions were pooled and concentrated to give 1-pent-2-enylimidazole, which was further purified by distillation, b.p. 134°/15 mmHg (19,995 x 10-s Pa).
    • Example 23 Preparation of 1-pent-4-enylimidazole
  • 1-Bromopent-4-ene (10.0 g, 0.067 mol) was added dropwise to a stirred, boiling mixture of imidazole (9.0 g, 0.132 mol) and sodium bicarbonate (11.0 g, 0.13 mol) in methanol (50 ml). Following the addition, the mixture was stirred and heated under reflux for 24 h.
  • After cooling, the reaction mixture was filtered and the filtrate concentrated under reduced pressure. The residue was dissolved in 2M-hydrochloric acid and this solution was washed with ether. The acid solution was basified with 1 OM-sodium hydroxide solution and the product was extracted with chloroform (3 x 50 ml). The combined extracts were dried (MgS04) and then concentrated to afford an oil which was purified on a silica gel column and elution with ethyl acetate/methanol (9:1). The product fractions were pooled and concentrated to give 1-pent-4-enylimidazole, which was further purified by distillation, b.p. 132°/12 mmHg. (15,996 x 10-s Pa).
    • Example 24
  • By the method described in the Biological Results in Example 7 above, the ED60 values were obtained for the compounds set out in Table 1.
    Figure imgb0017
    • Example 25 Tablet formulations
  • By the methods described in the Tablet formulation Examples described above, tablets were prepared of:
    • 1-n-butylimidazole
    • 1-(3-methylbutyl)imidazole
    • 1-crotylimidazole
    • 1-n-pentylimidazole
    • 1-cyclohexylmethylimidazole
    • 1-cyclopentylimidazole
    • 1-cycloheptylimidazole
    • 1-(pent-2-enyl)imidazole
    • 1-(pent-4-enyl)imidazole.
    • In each case the imidazole was present as a salt, e.g. the fumarate or perchlorate.
    Example 26 Injectable formulations
  • Injectable formulations were prepared by the method of the Injectable formulation in Example 12 above using the imidazoles mentioned in the immediately preceding Example.
    • Example 27 Salts of 1-Cyclooctylmethylimidazole A. Hydrogen Fumarate
  • A solution of fumaric acid (0.22 g) in hot ethanol (10 ml) was added to a solution of 1-cyclooctylmethylimidazole (0.38 g) in ethanol (4 ml). After boiling for 10 minutes the solution was evaporated to afford a white solid. Recrystallisation from ethyl acetate afforded 1-cyclooctylmethyl- imidazole hydrogen fumarate (0.42 g) as white needles, m.p. 147-148°.
    • B. Hydrogen Succinate
  • A solution of succinic acid (0.23 g) in ethanol (~5 ml) was added to a solution of 1-cyclooctylmethylimidazole (0.38 g) in ethanol (5 ml). Evaporation of the solution afforded a white solid. Recrystallisation of the solid from ethyl acetate afforded 1-cyclooctylmethylimidazole hydrogen succinate (0.27 g) as colourless plates, m.p. 86-87°.
    • C. Oxalate
  • A solution of oxalic acid (0.17 g) and 1-cyclooctylmethylimidazole (0.38 g) in ethanol (20 ml) was boiled for 0.25 h, when evaporation of the solution afforded a white solid. Recrystallisation of the solid from ethyl acetate/ethanol/petroleum ether (b.p. 40-60°C) afforded 1-cyclooctylmethylimidazole oxalate as white needles, m.p. 141-142°.
    • D. Hydrochloride
  • 1-Cyclooctylmethylimidazole (-0.3 g) was dissolved in dry ether (30 ml), when a stream of dry hydrogen chloride was passed through the solution at -20°C. The resulting white precipitate was filtered off under dry nitrogen and recrystallised from ethyl acetate/petroleum ether (b.p. 40-60°) to afford 1-cyclooctylmethylimidazole hydrochloride as a white solid, m.p. 20-22°C.
    • Example 28 Preparation of 1-Cyclohexylimidazole A. Cyclohexylaminoacetaldehyde diethyl acetal
  • A mixture of chloroacetaldehyde diethyl acetal (42.5 g) and cyclohexylamine (139.0 g) was stirred and heated under reflux for 4 hr. After cooling, water (150 ml) was added and the solution basified with sodium hydroxide solution (10 M). The resulting suspension was extracted with ether (3 x 200 ml) and the extracts dried over magnesium sulphate. Evaporation of the ether gave a brown oil. Distillation of the oil in vacuo afforded cyclohexylaminoacetaldehyde diethyl acetal, 38.52 g, b.p. 66-720/0.15 mmHg (0,19995 x 10-8 Pa).
    • B. 1-Cyclohexyl-2-thioimidazole
  • A mixture of cyclohexylaminoacetaldehyde diethyl acetal (21.5 g) and potassium thiocyanate (8.9 g) in 50% aqueous ethanol (50 ml) and concentrated hydrochloric acid (10 ml) was heated in an open flask on a steam bath for 3.5 hr. The resulting crystalline mass was dissolved in sodium hydroxide solution (-250 ml, 2M), the solution treated with charcoal, boiled and filtered. This solution was acidified with concentrated hydrochloric acid to afford the product as a white solid. Recrystallisation of the solid from ethyl acetate afforded 1-cyclohexyl-2-thioimidazole (13.2 g) as white plates, m.p. 181-182°.
    • C. 1-Cyc/ohexylimidazole
  • A mixture of 1-cyclohexyl-2-thioimidazole (2.0 g) and W2 Raney Nickel (~4.0 g), in ethanol (~25 ml) and ammonia solution (10 ml, 0.88) was vigorously stirred and heated under reflux for 2.0 hr. The catalyst was filtered off, and the solution evaporated to afford a white solid. Recrystallisation of the solid from petroleum ether (b.p. 60-80°) gave 1-cyclohexylimidazole (0.9 g) as white needles, m.p. 37-38°.
    • Example 29
  • By the method described in Example 1 above the following compounds were prepared:-
    • (a) 1-cyclooctylvinylimidazole
    • (b) 1-(2-cyclooctylethyl)imidazole
    • (c) 1-cyclooctylethylimidazole
    • (d) 1-(3-cyclooctylpropyl)imidazole
    • (e) 1-(3-methylcyclohept-2-enymethyl)imidazole
    • (f) 1-(3-methylcycloheptylmethyl)imidazole
    • (g) 1-(cyclohex-3-enylmethyl)imidazole m.p. 36-37°
    • (h) 1-cyclohexylethylimidazole b.p. 95―96°/0.2 mm (0,2666 x 10-8 Pa)
    • (i) 1-cyclobutylmethylimidazole b.p. 148-150°/25 mm (33,325 x 10-8 Pa)
    • (j) 1-cyclononylmethylimidazole

Claims (26)

1. A pharmaceutical formulation, adapted for administration to a human or animal subject, comprising an imidazole of the formula
Figure imgb0018
in which A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of from 1 to 3 carbon atoms, n is 0 or 1, and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9 carbon atoms, optionally substituted by one or more alkyl radicals each containing from 1 to 4 carbon atoms, or (A)n and R together form a straight-chain alkyl radical of from 4 to 7 carbon atoms or an alkenyl or alkynyl radical of from 4 to 9 carbon atoms, the imidazole being the free base of a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier therefor.
2. A pharmaceutical formulation as claimed in claim 1 characterised in that n is 1, A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of from 1 to 3 carbon atoms and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9 carbon atoms optionally substituted by one or more alkyl radicals each containing from 1 to 4 carbon atoms, the imidazole being the free base or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier therefor.
3. A pharmaceutical formulation as claimed in claim 1 characterised in that n is 1, R is selected from a cycloalkyl and a cycloalkenyl radical of from 6 to 8 carbon atoms, and A is-CHZ or -(CH2)2'
4. A pharmaceutical formulation as claimed in claim 1 characterised in that the imidazole is selected from 1-cyclohexylethyl-imidazole, and 1-cyclohex-3-enylmethylimidazole, and pharmaceutically acceptable acid addition salts thereof.
5. A pharmaceutical formulation as claimed in any of claims 1 to 4 characterised in that it is in the form of a tablet, capsule or parenterally acceptable injectable solution or suspension.
6. A pharmaceutical formulation as claimed in claim 1 comprising 1-cyclohexylmethyl-imidazole or a pharmaceutically acceptable acid addition salt thereof, in association with a pharmaceutically acceptable carrier therefor.
7. A pharmaceutical formulation as claimed in claim 1 comprising 1-cyclohexylmethyl-imidazole or a pharmaceutically acceptable acid addition salt thereof in the form of a tablet, capsule or parenterally acceptable injectable solution or suspension.
8. A pharmaceutical formulation as claimed in claim 1 comprising 1-cyclooctylmethyl-imidazole or a pharmaceutically acceptable acid addition salt thereof, in association with a pharmaceutically acceptable carrier therefor.
9. A pharmaceutical formulation as claimed in claim 1 comprising 1-cyclooctylmethyl-imidazole or a pharmaceutically acceptable salt thereof in the form of a tablet, capsule or parenterally acceptable injectable solution or suspension.
10. A tablet as claimed in claim 9 characterised in that it contains from 50 to 500 mg of the imidazole or a pharmaceutically acceptable salt thereof, said amount being the amount of the imidazole base present.
11. A method of preparing formulations as claimed in claim 1 characterised in that one admixes an imidazole or a pharmaceutically acceptable acid addition salt as defined in claim 1 with a pharmaceutically acceptable carrier therefor.
12. An imidazole characterised in that it is of formula
Figure imgb0019
in which n is 0 and R is a cycloalkyl or cycloalkenyl radical or from 4 to 9 carbon atoms and optionally substituted by one or more alkyl radicals each containing from 1 to 4 carbon atoms, with the proviso that R is not unsubstituted cyclohexyl, or a pharmaceutically acceptable acid addition salt thereof.
13. An imidazole as claimed in claim 12 with the further proviso that R is not substituted cyclohexyl.
14. An imidazole characterised in that it is of formula
Figure imgb0020
in which n = 1 and A and R together form an alkenyl radical of from 5 to 9 carbon atoms, or a pharmaceutically acceptable acid addition salt thereof.
15. An imidazole according to claim 12 which is 1-cyclopentylimidazole or 1-cycloheptylimidazole, or a pharmaceutically acceptable acid addition salt thereof.
16. An imidazole according to claim 14 which is 1-(pent-2-enyl)imidazole or 1-(pent-4-enyl)-imidazole, or a pharmaceutically acceptable acid addition salt thereof.
17. A pharmaceutical composition which comprises a compound according to any one of claims 12 to 16, and a pharmaceutically acceptable carrier therefor.
18. An imidazole of formula (I), as defined in claim 1, the imidazole being the free base or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of thrombo-embolic disorders of a mammal or mammalian tissue.
19. An imidazole according to claim 18 characterised in that n is 1, A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of from 1 to 3 carbon atoms and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9 carbon atoms optionally substituted by one or more alkyl radicals each containing from 1 to 4 carbon atoms.
20. An imidazole according to claim 18 in which (A)n and R together form an alkenyl radical of from 5 to 9 carbon atoms.
21. An imidazole according to claim 18 in which n = 0.
22. 1-Cyclooctylmethylimidazole or a pharmaceutically acceptable acid addition salt thereof, for use in the treatment or prophylaxis of thrombo-embolic disorders in a mammal.
23. 1-Cyclooctylmethylimidazole or a pharmaceutically acceptable acid addition salt thereof for use in the treatment or prophylaxis of thrombi in a mammal.
24. 1-Cyclooctylmethylimidazole or a pharmaceutically acceptable acid addition salt thereof for use in the treatment or prophylaxis of myocardial infarcation in a mammal.
25. 1-Cyclohexylmethylimidazole or a pharmaceutically acceptable acid addition salt thereof for use in the treatment or prophylaxis of thrombo-embolic disorders in a mammal.
26. A pharmaceutical formulation according to any one of claims 1 to 10 for use in the treatment or prophylaxis of a thrombo-embolic disorder in a mammal.
EP78100754A 1977-08-26 1978-08-25 Pharmaceutical formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders Expired EP0000951B1 (en)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
GB3591277 1977-08-26
GB3591377 1977-08-26
GB3591277 1977-08-26
GB3591377 1977-08-26
GB398378 1978-02-01
GB398378 1978-02-01
GB398478 1978-02-01
GB398478 1978-02-01
GB3252678 1978-08-08
GB7832526 1978-08-08
GB7832536 1978-08-08
GB3253678 1978-08-08
GB7834106A GB2006752B (en) 1977-08-26 1978-08-22 Imidazole derivatives and salts thereof their synthesis and intermediates and pharmaceutical formulations
GB3410678 1978-08-22

Publications (2)

Publication Number Publication Date
EP0000951A1 EP0000951A1 (en) 1979-03-07
EP0000951B1 true EP0000951B1 (en) 1984-05-23

Family

ID=27562526

Family Applications (1)

Application Number Title Priority Date Filing Date
EP78100754A Expired EP0000951B1 (en) 1977-08-26 1978-08-25 Pharmaceutical formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders

Country Status (4)

Country Link
US (1) US4284641A (en)
EP (1) EP0000951B1 (en)
JP (1) JPS5455568A (en)
DE (1) DE2862409D1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0003732B1 (en) * 1978-02-01 1983-10-19 The Wellcome Foundation Limited Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations thereof
EP0055991A3 (en) * 1978-10-02 1982-08-11 Merck & Co. Inc. Lysosomotropic detergent therapeutic agents, compositions containing them and their uses
GB2044754B (en) * 1978-11-14 1983-05-05 Eisai Co Ltd Imidazoles
US4430445A (en) 1979-07-19 1984-02-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel basic imidazolylmethylstyrene compound, its polymer, a process for the preparation thereof and a use as ion exchange resin
DE2944663A1 (en) * 1979-11-06 1981-05-14 Bayer Ag, 5090 Leverkusen IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS
DE2944662A1 (en) * 1979-11-06 1981-05-14 Bayer Ag, 5090 Leverkusen CYCLOHEPTATRIENYLIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINAL PRODUCTS
JPS5681566A (en) * 1979-12-05 1981-07-03 Yoshitomi Pharmaceut Ind Ltd Imidazole derivative
US4731363A (en) * 1979-12-26 1988-03-15 Hoffmann-La Roche Inc. Thromboxane synthase inhibitors as insulin lowering agents and antiobesity agents
US4522948A (en) * 1981-04-24 1985-06-11 Syntex (U.S.A.) Inc. Spermicidal substituted 1-(cycloalkyl)alkylimidazoles
ES523609A0 (en) * 1982-07-05 1985-03-01 Erba Farmitalia PROCEDURE FOR PREPARING N-IMIDAZOLYLIC DERIVATIVES OF BICYCLE COMPOUNDS.
EP0121081B1 (en) * 1983-03-03 1991-01-30 BASF Aktiengesellschaft Azolylmethylcycloalkanes, process for their preparation and their therapeutical use
US4992459A (en) * 1983-04-12 1991-02-12 Smithkline Beecham Corporation Dopamine-β-hydroxylase inhibitors
CA1249832A (en) * 1984-02-03 1989-02-07 Shionogi & Co., Ltd. Azolyl cycloalkanol derivatives and agricultural fungicides
US4659730A (en) * 1984-06-18 1987-04-21 Eli Lilly And Company Aromatase inhibiting imidazole derivatives
US4634711A (en) * 1985-08-02 1987-01-06 Smithkline Beckman Corporation Pyridylalkyl imidazole-2-thiols
US4719223A (en) * 1985-10-31 1988-01-12 Smithkline Beckman Corporation Imidazolethiol dopamine-beta-hydroxylase inhibitors
US4743613A (en) * 1986-04-08 1988-05-10 Smithkline Beckman Corporation Ester prodrugs of dopamine-β-hydroxylase, inhibitors, composition containing them, and method of using them to inhibit dopamine-β-hydroxylase activity
US4837333A (en) * 1987-05-14 1989-06-06 G. D. Searle & Co. Substituted alkylidene imidazoles
US4876266A (en) * 1987-12-31 1989-10-24 Smithkline Beckman Corporation 1-aralkyl-2-mercaptoimidazolines as DBH inhibitors
US5091454A (en) * 1988-08-03 1992-02-25 Velsicol Chemical Corporation Hot melt adhesive composition
IL91542A0 (en) * 1988-10-06 1990-04-29 Erba Carlo Spa N-imidazolyl-and n-imidazolyl-methyl derivatives of substituted bicyclic compounds,their preparation and pharmaceutical compositions containing them
US4968713A (en) * 1989-07-31 1990-11-06 Merck & Co., Inc. Certain imidazole compounds as transglutaminase inhibitors
US5359073A (en) * 1992-11-24 1994-10-25 G. D. Searle & Co. Substituted-phenyl (N,N'-cycloalkyl/alkyl carboxamide)-1H/3H-imidazo[4,5-b]pyridine compounds as PAF antagonists
US5262426A (en) * 1993-01-22 1993-11-16 G. D. Searle & Co. N,N'-cycloalkyl/alkyl carboxamide 4H-imidazo-[4,5-b]pyridine compounds as PAF antagonists
US5360907A (en) * 1993-06-14 1994-11-01 G.D. Searle & Co. Pyrrolo[3,2-B]pyridinylalkyl benzamide derivatives
US5652363A (en) * 1995-10-05 1997-07-29 C.D. Searle & Co. Pyrido-1,4-oxazinylalkyl-benzamide derivatives
JP2013540145A (en) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス Selective CYP11B1 inhibitor for the treatment of cortisol-dependent diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1213413B (en) 1963-12-05 1966-03-31 Basf Ag Process for the preparation of N-alkylimidazoles
DE1620362A1 (en) 1966-05-04 1970-04-02 Shell Int Research Process for the production of N-alkyl- or N-alkenylimidazoles
GB1164564A (en) * 1967-08-21 1969-09-17 Shell Int Research Novel Cyclobexylpentadienone Acid Derivatives, the preparation thereof and Compositions containing the same
ES348533A2 (en) * 1967-12-22 1969-05-01 Trossinger Metallstimmenfab H Signal reproducer
US3541109A (en) * 1968-06-25 1970-11-17 Du Pont 1-substituted imidazoles useful in acth reserve assay
US3637731A (en) * 1968-07-18 1972-01-25 Du Pont 1-(alkylsubstituted phenyl)imidazoles useful in acth reserve assay
FR1603793A (en) 1968-12-17 1971-05-24 Substd imidazoles intermediates for insecticides
CH548398A (en) * 1971-02-13 1974-04-30 Basf Ag PROCESS FOR THE MANUFACTURING OF SUBSTITUTED IMIDAZOLES.
GB1364312A (en) 1972-01-25 1974-08-21 Beecham Group Ltd Biologically active imidazoles
IE40911B1 (en) * 1974-04-11 1979-09-12 Schering Ag Imidazole derivatives and process for their manufacture
US3927017A (en) * 1974-06-27 1975-12-16 Janssen Pharmaceutica Nv 1-({62 -Aryl-{62 -R-ethyl)imidazoles
US3991201A (en) * 1974-06-27 1976-11-09 Janssen Pharmaceutica N.V. 1-(β-Aryl-β-R-ethyl)imidazoles as antimicrobial agents
DE2533211A1 (en) 1975-07-24 1977-02-10 Heumann Ludwig & Co Gmbh Imidazole deriv. prepn. - by reacting iminoester or amidine or their salts with alpha-acylamino ketone in liquid ammonia
US4036975A (en) * 1975-07-28 1977-07-19 Xyntex (U.S.A) Inc. 1-[2-(1-Adamantyl)-2-(R-thio)ethyl]imidazoles and 1-[2-(1-adamantyl)-2-(R-oxy)ethyl]imidazoles
US4115578A (en) * 1975-12-18 1978-09-19 Rohm And Haas Company 1-Substituted aralkyl imidazoles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, VOL. 80, No. 1, 1978, pp. 236-242 *
BIOCHEMICAL PHARMACOLOGY, 23, 2377-2386 (1974) *

Also Published As

Publication number Publication date
US4284641A (en) 1981-08-18
EP0000951A1 (en) 1979-03-07
JPS5455568A (en) 1979-05-02
DE2862409D1 (en) 1984-06-28

Similar Documents

Publication Publication Date Title
EP0000951B1 (en) Pharmaceutical formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders
EP0003732B1 (en) Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations thereof
EP1439837B1 (en) Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
EP0015002B1 (en) 1-substituted imidazoles, and salts thereof, a method for their preparation and pharmaceutical formulations thereof
EP0000950B1 (en) Imidazole derivatives and salts thereof and their synthesis
CA1111433A (en) Imidazole derivatives and their salts
US4431815A (en) 1-[3-(2,4-Dichlorophenyl)propyl]imidazole and salts thereof
US4357340A (en) Imidazole derivatives and angina pectoris
US4396771A (en) Imidazole derivatives and salts thereof
US4317830A (en) Treatment of shock
US4405634A (en) Imidazole derivatives for treating myocardial infarction
US4425354A (en) Imidazole derivatives and salts thereof, their synthesis, and intermediates, and pharmaceutical formulations
KR820001912B1 (en) Process for preparing imidazoles
EP0106060B1 (en) Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations
NZ188693A (en) 1-arylalkylimidazoles and pharmaceutical compositions
HU181992B (en) Process for preparing imidazole derivatives and salts thereof
KR820001911B1 (en) Process for preparing imidazole derivatives
KR830000614B1 (en) Method for preparing imidazole derivative
IE47650B1 (en) Pharmaceutical formulations comprising imidazole derivatives and salts
EP0019223A1 (en) Optically active hydantoin derivatives, their synthesis, pharmaceutical formulations containing them, and intermediates

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE FR GB LU NL SE

17P Request for examination filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE FR GB LU NL SE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19840607

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19840608

Year of fee payment: 7

REF Corresponds to:

Ref document number: 2862409

Country of ref document: DE

Date of ref document: 19840628

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19840630

Year of fee payment: 7

Ref country code: BE

Payment date: 19840630

Year of fee payment: 7

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19840831

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19841004

Year of fee payment: 7

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19850831

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19860826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Effective date: 19860831

BERE Be: lapsed

Owner name: THE WELLCOME FOUNDATION LTD

Effective date: 19860831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19870301

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
GBPC Gb: european patent ceased through non-payment of renewal fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19870430

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19870701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19881117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19890831

EUG Se: european patent has lapsed

Ref document number: 78100754.7

Effective date: 19870812